BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $GMAB readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05451810-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~Epcoritamab readout (P2) · Genmab $GMAB
DESCRIPTION:A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcorit
 amab Administered in the Outpatient Setting in Adult Participants With Rel
 apsed or Refractory Diffuse Large B-Cell L…\n\nPrimary completion date: 
 2027-03 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2025-08-14 (+18.5 months)\nPhase 2 · Oncology · Diffuse Large B-Cell Ly
 mphoma\, Classic Follicular Lymphoma\nEnrollment: 184 · Sites: 72\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/rad
 ar.html?nct=NCT05451810\nhttps://clinicaltrials.gov/study/NCT05451810
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05451810
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~EPCORE DLBCL-2 readout (P3) · Genmab $GMAB
DESCRIPTION:A Study to Evaluate Change in Disease Activity of Subcutaneous 
 (SC) Epcoritamab Combined With Intravenous and Oral Rituximab\, Cyclophosp
 hamide\, Doxorubicin Hydrochloride\, Vincrist…\n\nPrimary completion dat
 e: 2027-06 (estimated) — month only\, shown on the 1st\nOriginally plann
 ed: 2024-07-29 (+34.1 months)\nPhase 3 · Oncology · Diffuse Large B-Cell
  Lymphoma\nEnrollment: 900 · Sites: 331\n\nPrimary completion = last part
 icipant's primary-endpoint data collected\; topline results usually follow
  weeks to months later. Sponsor-reported\, often an estimate. Not investme
 nt advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT05578976\nh
 ttps://clinicaltrials.gov/study/NCT05578976
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05578976
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635824-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Acasunlimab readout (P3) · Genmab $GMAB
DESCRIPTION:Trial to Evaluate Acasunlimab and Pembrolizumab Combination Sup
 eriority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (AB
 BIL1TY NSCLC-06)\n\nPrimary completion date: 2027-07-30 (estimated)\nOrigi
 nally planned: 2027-01-31 (+5.9 months)\nPhase 3 · Oncology · PD-L1-posi
 tive\, Locally Advanced (Unresectable Stage IIIB/C…\nEnrollment: 191 · 
 Sites: 247\n\nPrimary completion = last participant's primary-endpoint dat
 a collected\; topline results usually follow weeks to months later. Sponso
 r-reported\, often an estimate. Not investment advice.\n\nhttps://trialson
 ar.netlify.app/radar.html?nct=NCT06635824\nhttps://clinicaltrials.gov/stud
 y/NCT06635824
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06635824
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604766-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~RAINFOL-02 readout (P3) · Genmab $GMAB
DESCRIPTION:An Extension Study to Assess the Efficacy of Rina-S Compared to
  Treatment of Investigator's Choice in Participants With Platinum Resistan
 t Ovarian Cancer in China\n\nPrimary completion date: 2027-09 (estimated) 
 — month only\, shown on the 1st\nPhase 3 · Oncology · Platinum-resista
 nt Ovarian Cancer\nEnrollment: 82 · Sites: 17\n\nPrimary completion = las
 t participant's primary-endpoint data collected\; topline results usually 
 follow weeks to months later. Sponsor-reported\, often an estimate. Not in
 vestment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07604
 766\nhttps://clinicaltrials.gov/study/NCT07604766
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07604766
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
